leadf
logo-loader
viewMaxCyte Inc

MaxCyte appoints former healthcare analyst Amanda Murphy as its chief financial officer

Murphy previously served as a managing director of US investment house BTIG and has specialized in gene therapy, gene editing and cell therapy equity research for both burgeoning private and established public healthcare companies

Handshake
Ron Holtz, who has served as MaxCyte's CFO since 2005, will become senior vice president and chief accounting officer

MaxCyte, Inc. (LON:MXCT) (LON:MXCL) has announced that former healthcare analyst Amanda Murphy has joined the company as its chief financial officer (CFO) from today.

The company added that Ron Holtz, who has served as MaxCyte's CFO since 2005, will become senior vice president and chief accounting officer (SVP & CAO).

The global cell-based therapies and life sciences company noted that, before joining MaxCyte, Murphy served as a managing director of US investment house BTIG. She has specialized in gene therapy, gene editing and cell therapy equity research for both burgeoning private and established public healthcare companies.

READ: MaxCyte expands phase I cancer trial to two further centres

Prior to BTIG, she was a partner and healthcare analyst at William Blair & Company, focused on diagnostic services and life sciences. She received a BS in biology from Boston College's honours programme, and an MBA in finance, accounting and economics from the Kellogg Graduate School of Management at Northwestern University.

In a statement, MaxCyte president & CEO, Doug Doerfler commented: "We are extremely pleased to welcome Amanda, who served as a successful, respected analyst in both the enabling technology and cell therapy sectors, to the MaxCyte team at this pivotal moment for the Company and the industry.

“We are collectively witnessing the beginning of cell and gene therapies' impact on revolutionizing medical treatment and saving human lives, and Amanda's w wealth of experience - her deep understanding of the financial community and her unique, insightful, strategic view of the cell therapy sector - will support the continued development and expansion of MaxCyte's contribution in this space."

Murphy added: "From my work as a healthcare analyst, I've long been familiar with MaxCyte's central role in the cell therapy space, as the inventors of the premier cell engineering enabling technology and the go-to partner for the world's leading gene editing and cell therapy companies. It's exciting to join MaxCyte at this time, as the cell therapy industry continues to accelerate the development of advanced life-saving therapies, and as the company looks to evolve its business model with the spin-off of CARMA Cell Therapies and a potential listing on the Nasdaq exchange."

In his new role as CAO and SVP, Holtz will retain key elements of his former role as CFO, including overseeing accounting and budgeting/forecasting and supporting key business operations. MaxCyte’s board of directors is unchanged with Holtz remaining as an executive member.

Holtz said: "As MaxCyte grows, evolves, and prepares for entry into the US public equity market, it's the ideal time for us to bring in someone with Amanda's unique capital markets perspective and deep insights into the cell therapy space.  I am also looking forward to continuing to focus where my primary interests and skillsets can best support MaxCyte's future."

Quick facts: MaxCyte Inc

Price: 410 GBX

AIM:MXCT
Market: AIM
Market Cap: £316.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

3 min read